Patient-Derived Xenograft Models: An Emerging Platform for
Translational Cancer Research

J 2014

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

HIDALGO, Manuel; Frederic AMANT; Andrew V. BIANKIN; Eva BUDINSKÁ; Annete T. BYRNE et al.

Základní údaje

Originální název

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Autoři

Vydání

Cancer Discovery, Philadelphia, American Association for Cancer Research Inc. 2014, 2159-8274

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 19.453

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00078130

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

HUMAN PANCREATIC-CANCER; TUMOR XENOGRAFTS; NUDE-MICE; COLORECTAL-CANCER; STEM-CELLS; IN-VIVO; PERSONALIZED CHEMOTHERAPY; THERAPEUTIC RESPONSE; IMMUNODEFICIENT MICE; DRUG DEVELOPMENT

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 1. 2015 14:10, Soňa Böhmová

Anotace

V originále

Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field.

Citovat

HIDALGO, Manuel; Frederic AMANT; Andrew V. BIANKIN; Eva BUDINSKÁ; Annete T. BYRNE; Carlos CALDAS; Robert B. CLARKE; Steven de JONG; Jos JONKERS; Gundhild Mari MAELANDSMO; Sergio ROMAN-ROMAN; Joan SEOANE; Livio TRUSOLINO a Alberto VILLANUEVA. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery. Philadelphia: American Association for Cancer Research Inc., 2014, roč. 4, č. 9, s. 998-1013. ISSN 2159-8274. Dostupné z: https://doi.org/10.1158/2159-8290.CD-14-0001.

@article{1215472,
   author = {Hidalgo, Manuel and Amant, Frederic and Biankin, Andrew V. and Budinská, Eva and Byrne, Annete T. and Caldas, Carlos and Clarke, Robert B. and Jong, Steven de and Jonkers, Jos and Maelandsmo, Gundhild Mari and RomanandRoman, Sergio and Seoane, Joan and Trusolino, Livio and Villanueva, Alberto},
   article_location = {Philadelphia},
   article_number = {9},
   doi = {https://doi.org/10.1158/2159-8290.CD-14-0001},
   keywords = {HUMAN PANCREATIC-CANCER; TUMOR XENOGRAFTS; NUDE-MICE; COLORECTAL-CANCER; STEM-CELLS; IN-VIVO; PERSONALIZED CHEMOTHERAPY; THERAPEUTIC RESPONSE; IMMUNODEFICIENT MICE; DRUG DEVELOPMENT},
   language = {eng},
   issn = {2159-8274},
   journal = {Cancer Discovery},
   title = {Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research},
   volume = {4},
   year = {2014}
}

TY  - JOUR
ID  - 1215472
AU  - Hidalgo, Manuel - Amant, Frederic - Biankin, Andrew V. - Budinská, Eva - Byrne, Annete T. - Caldas, Carlos - Clarke, Robert B. - Jong, Steven de - Jonkers, Jos - Maelandsmo, Gundhild Mari - Roman-Roman, Sergio - Seoane, Joan - Trusolino, Livio - Villanueva, Alberto
PY  - 2014
TI  - Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
JF  - Cancer Discovery
VL  - 4
IS  - 9
SP  - 998-1013
EP  - 998-1013
PB  - American Association for Cancer Research Inc.
SN  - 21598274
KW  - HUMAN PANCREATIC-CANCER
KW  - TUMOR XENOGRAFTS
KW  - NUDE-MICE
KW  - COLORECTAL-CANCER
KW  - STEM-CELLS
KW  - IN-VIVO
KW  - PERSONALIZED CHEMOTHERAPY
KW  - THERAPEUTIC RESPONSE
KW  - IMMUNODEFICIENT MICE
KW  - DRUG DEVELOPMENT
N2  - Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field.
ER  -

HIDALGO, Manuel; Frederic AMANT; Andrew V. BIANKIN; Eva BUDINSKÁ; Annete T. BYRNE; Carlos CALDAS; Robert B. CLARKE; Steven de JONG; Jos JONKERS; Gundhild Mari MAELANDSMO; Sergio ROMAN-ROMAN; Joan SEOANE; Livio TRUSOLINO a Alberto VILLANUEVA. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. \textit{Cancer Discovery}. Philadelphia: American Association for Cancer Research Inc., 2014, roč.~4, č.~9, s.~998-1013. ISSN~2159-8274. Dostupné z: https://doi.org/10.1158/2159-8290.CD-14-0001.

Přehled o publikaci